A Trial to Investigate Pharmacokinetics, Safety and Tolerability of Insulin Degludec/Liraglutide (A3) Compared With Insulin Degludec and Liraglutide in Healthy Subjects

Registration

Registration

NCT01319240

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE1

Masking

DOUBLE

Status

COMPLETED

Enrollment

24

Start

2011-03

Primary completion

2011-05

Lead sponsor

Novo Nordisk A/S

Conditions

Diabetes; Healthy

Interventions

DRUG:insulin degludec; DRUG:insulin degludec/liraglutide; DRUG:liraglutide

Results posted

FALSE

Secondary identifiers

EUDRACT_NUMBER:2010-021190-36; OTHER:U1111-1119-2417

Registered primary outcomes

• The area under insulin degludec concentration-time curve [from 0-infinity hours after trial product administration]
• The area under liraglutide concentration-time curve [from 0-infinity hours after trial product administration]